talquetamab,dexamethasone,belantamab mafodotin
janssen,gsk
fascinating point by at #ims22 - 90% of pts had baseline issues *before* belantamab exposure when screened. makes sense given age group, dex exposure. but also similar to how talquetamab is teaching us how many pts have baseline taste issues beforehand. 
Asst Professor @UWMedicine @fredhutch, s/p @UCSFCancer heme/onc ?? CAR-T training. #MMsm #TcellRx #cellphonesandcelltherapies ????

COI: https://t.co/3Uuojuio6R